Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 32

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 32
---
 to Bausch + Lomb x Experienced in acquiring and managing drug pipelines: led transactions to acquire 6 product candidates while CFO of ISTA Pharmaceuticals Selected Recent Public Company Experience ▪ Independent Director | Harrow (Nasdaq: HROW) ▪ Former Independent Director | Harpoon Therapeutics (Nasdaq: HARP) ▪ Former Independent Director | Nicox SA (EPA: ALCOX) ▪ Former CFO | Evolus (Nasdaq: EOLS) ▪ Former CFO | Revance Therapeutics (Nasdaq: RVNC) ▪ Former CFO | ISTA Pharmaceuticals (Nasdaq: ISTA) ▪ Former VP Business Development | Allergen (NYSE: AGN) ▪ Former Group Product Manager | Bio - Rad (NYSE: BIO) vs © Copyright DYNAVAX 2025 Jeffrey Farrow Chief Financial Officer at Tarsus Pharmaceuticals, a biopharmaceutical eye care company Potential conflict of interest: Mr. Farrow serves as a director of Clover Pharmaceuticals, a commercial supply partner for Dynavax’s CpG 1018 adjuvant No additive skillsets to our board: No additional or differentiated perspective or skills relative to our current Board No vaccine research experience: Primarily served in financial roles throughout his career Poor track record of value creation: Mr. Farrow’s only public board experience resulted in negative TSR relative to the Russell 3000

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx We Are Executing a Clear Strategy That is Generating Record Results and Delivering Strong Returns For Stockholders 43 | Source: Factset ; Market data as of Apr - 2025 1 Based on Dynavax stock price between April 17, 2020, and Apr 17, 2025. 2 Reflects CAGR for net Heplisav - B sales from FY 2020 to FY 2024. 3 Not accounting for bottom line profitability first achieved in 2021 from CpG - 1018 adjuvant sales, related to the COVID - 1 pandemic. 4 Based on 3 - month average at time of authorization. © Copyright DYNAVAX 2025 Our Strategy is the Only Path to Deliver Superior Stockholder Value… Drive growth in HE